Story perspectives

Servier to Acquire Day One for $2.5 Billion

3/6/2026

Summary

Story summary

Servier, a French pharmaceutical company, will acquire Day One Biopharmaceuticals for about $2.5 billion in cash at $21.50 per share.
The deal delivers a 68% premium to Day One's close and strengthens Servier's oncology pipeline.
The transaction advances pediatric low-grade glioma therapies as part of Servier's 2030 goal.
It is subject to customary closing conditions and is expected to close in Q2 2026, with Day One's Board recommending shareholders tender.

1 of 1

Story summary

Servier, a French pharmaceutical company, will acquire Day One Biopharmaceuticals for about $2.5 billion in cash at $21.50 per share.
The deal delivers a 68% premium to Day One's close and strengthens Servier's oncology pipeline.
The transaction advances pediatric low-grade glioma therapies as part of Servier's 2030 goal.
It is subject to customary closing conditions and is expected to close in Q2 2026, with Day One's Board recommending shareholders tender.